Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-04-30

Azodicarbonamide: a potential new drug in AISQ

Objective



In view of the emergence of resistant strain, even under combination therapy,the search for new active drugs, preferably with a new mechanism of action likeAzodicarbonamide, is of the greatest importance from the public health point ofview. Moreover, due to the costs of such combination therapies, these drugsare not available for the majority of patients and for the populations mostconcerned in the countries in development. The goal of the RTD will be toconduct a Phase II study with Azodicarbonamide following the recommendations ofthe expêrts of the European Community. Based on the optimum dose derived from the Phase II a study, a European study will be conducted in a sufficient numberof HIV infected patients from European clinical centers (Three of them havealready signed an agreement). The economical, ethical and social problemconcerning a new drug in AIDS are reviewed.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Topic(s)

Data not available

Call for proposal

Data not available

Coordinator

Hubriphar SA
EU contribution
No data
Address
40,Avenue Joseph Wybran
1070 Bruxelles
Belgium

See on map

Total cost
No data
My booklet 0 0